Onward and upward the market goes, with December providing further cheer as new record highs for the S&P 500 were notched in the …
Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) …
Black Friday is past. So is Cyber Monday.
Stemline Therapeutics (STML) announced the European Medicines Agency (EMA) is granting accelerated assessment for the company’s marketing authorization for oral treatment, Elzonris. The …
Stemline Therapeutics Inc (NASDAQ:STML) was mentioned cautiously in an article by Adam Feuerstein of TheStreet. According to to the report, a patient died …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ:STML) with a price target of $62, which represents a …
In a research report issued Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics (NASDAQ:STML) with a price target …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ:STML) with a price …
In a research report published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) with a $62 price target, following today’s news of the opening of STML’s Investigational New …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) and a price target of $62.